8-K/A: Therapeutic Solutions International Subsidiary Enters Exclusive Patent License Agreement

Therapeutic Solutions International's partially owned subsidiary, Campbell Neurosciences, Inc., has entered into an exclusive patent license agreement.

Summary

• Therapeutic Solutions International, Inc. has announced that its partially owned subsidiary, Campbell Neurosciences, Inc., entered into an exclusive patent license agreement on May 30, 2024.
• The agreement is detailed in exhibit 10.1, which includes patent publication number 20220280574.
• This filing is an amendment to a previous filing, correcting an error where board minutes were provided instead of the license agreement.

Sentiment

Score: 7

Explanation: The announcement of an exclusive patent license agreement is generally positive, indicating potential for future growth and revenue. However, the document lacks specific details about the financial impact or the technology's market potential, which limits the overall positive sentiment.

Positives

• The exclusive patent license agreement could provide Campbell Neurosciences, Inc. with a competitive advantage.
• The agreement may lead to new revenue streams for the company.

Risks

• The success of the agreement depends on the commercial viability of the licensed technology.
• There is a risk that the technology may not perform as expected.

Management Comments

• Timothy Dixon, Chief Executive Officer of Therapeutic Solutions International, Inc., signed the report on behalf of the company.

Industry Context

Patent licensing is a common practice in the biotechnology and pharmaceutical industries, allowing companies to leverage intellectual property for research, development, and commercialization. This agreement suggests that Therapeutic Solutions International is actively managing its intellectual property portfolio to create value.

Comparison to Industry Standards

• Many biotechnology companies use patent licensing to expand their product pipeline and market reach.
• Similar agreements are common among companies like Moderna, BioNTech, and Gilead Sciences, which often license technologies to accelerate drug development and commercialization.
• The success of this agreement will depend on the specific terms and the market potential of the licensed technology, which is not detailed in this document.

Stakeholder Impact

• Shareholders may view this agreement positively as it could lead to future revenue and growth.
• Employees of Campbell Neurosciences may be involved in the development and commercialization of the licensed technology.

Key Dates

Keywords

patent license, Therapeutic Solutions International, Campbell Neurosciences, intellectual property, agreement